Skip to main content
SpringerLink
Log in

The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

A substantial volume of literature exists linking proton pump inhibitor (PPI) use with a multitude of serious adverse events. There is uncertainty, however, over whether these associations are clinically important. Excessive concern about PPI-related adverse events may leave patients at risk of harm by leaving acid-related upper gastrointestinal disease untreated. Conversely, the risk of treatments may outweigh the benefits if any of the purported adverse events are directly caused by PPI use; this is of particular concern where indications for PPI use are not present. In this paper, we review the studies which have reported associations between adverse events and PPI use, discuss the proposed mechanisms of action, grade the confidence in whether these associations are truly causal, and provide advice regarding balancing the benefits of PPI use against their possible harms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. IMS Institute for Healthcare Informatics. Declining medicine use and costs: For better or worse? A review of the use of medicines in the United States in 2012. Burlington, MA.

  2. Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2015. AJHP. 2015;72(9):717–36.

    PubMed  Google Scholar 

  3. Jaisser F, Beggah AT. The nongastric H+-K+-ATPases: molecular and functional properties. Am J Physiol. 1999;276(6):F812–24.

    CAS  PubMed  Google Scholar 

  4. Novak I, Wang J, Henriksen KL, Haanes KA, Krabbe S, Nitschke R, et al. Pancreatic bicarbonate secretion involves two proton pumps. J Biol Chem. 2011;286(1):280–9.

    Article  CAS  PubMed  Google Scholar 

  5. Wang J, Barbuskaite D, Tozzi M, Giannuzzo A, Sorensen CE, Novak I. Proton pump inhibitors inhibit pancreatic secretion: role of gastric and non-gastric H+/K+-ATPases. PLoS One. 2015;10(5):e0126432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther. 1990;4(2):131–8.

    Article  CAS  PubMed  Google Scholar 

  7. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–63.

    Article  CAS  PubMed  Google Scholar 

  8. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–88.

    Article  CAS  PubMed  Google Scholar 

  9. Sharma BK, Santana IA, Wood EC, Walt RP, Pereira M, Noone P, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. BMJ. 1984;289(6447):717–9.

    Article  CAS  PubMed  Google Scholar 

  10. Del Piano M, Anderloni A, Balzarini M, Ballare M, Carmagnola S, Montino F, et al. The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the “gastric barrier effect” in patients chronically treated with PPI: a pilot study. J Clin Gastroenterol. 2012;46(Suppl):S18–26.

    Article  PubMed  Google Scholar 

  11. Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–9.

    Article  CAS  PubMed  Google Scholar 

  12. Altman KW, Chhaya V, Hammer ND, Pavlova S, Vesper BJ, Tao L, et al. Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains. Laryngoscope. 2008;118(4):599–604.

    Article  CAS  PubMed  Google Scholar 

  13. Parsons BN, Ijaz UZ, D’Amore R, Burkitt MD, Eccles R, Lenzi L, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017;13(11):e1006653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Husebye E, Skar V, Hoverstad T, Melby K. Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. Gut. 1992;33(10):1331–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scand J Gastroenterol. 1996;31(9):875–80.

    Article  CAS  PubMed  Google Scholar 

  16. Castiglione F, Del Vecchio Blanco G, Rispo A, Petrelli G, Amalfi G, Cozzolino A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol. 2000;31(1):63–6.

    Article  CAS  PubMed  Google Scholar 

  17. McLoughlin GA, Hede JE, Temple JG, Bradley J, Chapman DM, McFarland J. The role of IgA in the prevention of bacterial colonization of the jejunum in the vagotomized subject. Br J Surg. 1978;65(6):435–7.

    Article  CAS  PubMed  Google Scholar 

  18. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.

    Article  CAS  PubMed  Google Scholar 

  19. Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27–36.

    Article  CAS  PubMed  Google Scholar 

  20. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother. 2006;50(11):3901–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–84.

    Article  CAS  PubMed  Google Scholar 

  23. De La Cochetiere MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Dore J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol. 2005;43(11):5588–92.

    Article  CAS  Google Scholar 

  24. Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883 e9–885 e9.

    Google Scholar 

  25. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.

    Article  CAS  PubMed  Google Scholar 

  26. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.

    Article  CAS  PubMed  Google Scholar 

  27. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784–91.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56 (quiz 57).

    Article  PubMed  Google Scholar 

  29. Hassing RJ, Verbon A, de Visser H, Hofman A, Stricker BH. Proton pump inhibitors and gastroenteritis. Eur J Epidemiol. 2016;31(10):1057–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Xu HB, Wang HD, Li CH, Ye S, Dong MS, Xia QJ, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. GMR. 2015;14(3):7490–501.

    Article  CAS  PubMed  Google Scholar 

  31. Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64(4):1265–72.

    Article  CAS  PubMed  Google Scholar 

  32. Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–60.

    Article  CAS  PubMed  Google Scholar 

  33. Tergast TL, Wranke A, Laser H, Gerbel S, Manns MP, Cornberg M, et al. Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int. 2018;38(9):1602–13.

    Article  CAS  PubMed  Google Scholar 

  34. Song H, Ekheden IG, Zheng Z, Ericsson J, Nyren O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015;351:h3867.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993;88(10):1801–2.

    CAS  PubMed  Google Scholar 

  36. Stoschus B, Dominguez-Munoz JE, Kalhori N, Sauerbruch T, Malfertheiner P. Effect of omeprazole on Helicobacter pylori urease activity in vivo. Eur J Gastroenterol Hepatol. 1996;8(8):811–3.

    CAS  PubMed  Google Scholar 

  37. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36(1):12–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kuipers EJ, Uyterlinde AM, Pena AS, Hazenberg HJ, Bloemena E, Lindeman J, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90(9):1401–6.

    CAS  PubMed  Google Scholar 

  39. Stolte M, Meining A, Schmitz JM, Alexandridis T, Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998;12(3):247–53.

    Article  CAS  PubMed  Google Scholar 

  40. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992;51(Suppl 1):82–92.

    Article  PubMed  Google Scholar 

  41. Creutzfeldt W, Lamberts R. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion. 1992;51(Suppl 1):76–81.

    Article  PubMed  Google Scholar 

  42. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology. 1997;112(3):707–17.

    Article  CAS  PubMed  Google Scholar 

  43. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5(4):206–14.

    Article  CAS  PubMed  Google Scholar 

  44. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334(16):1018–22.

    Article  CAS  PubMed  Google Scholar 

  45. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19(16):2560–8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706 e5–1719 e5.

    Article  CAS  Google Scholar 

  48. Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther. 2016;44(9):915–25.

    Article  CAS  PubMed  Google Scholar 

  49. Kinoshita Y, Tojo M, Yano T, Kitajima N, Itoh T, Nishiyama K, et al. Incidence of fundic gland polyps in patients without familial adenomatous polyposis. Gastrointest Endosc. 1993;39(2):161–3.

    Article  CAS  PubMed  Google Scholar 

  50. Wu TT, Kornacki S, Rashid A, Yardley JH, Hamilton SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol. 1998;22(3):293–8.

    Article  CAS  PubMed  Google Scholar 

  51. Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010;32(9):1124–8.

    Article  CAS  PubMed  Google Scholar 

  52. Pascua MF, Kedia P, Weiner MG, Holmes J, Ellenberg J, Lewis JD. Microscopic colitis and medication use. Clin Med Insights Gastroenterol. 2010;2010(3):11–9.

    PubMed  PubMed Central  Google Scholar 

  53. Fernandez-Banares F, de Sousa MR, Salas A, Beltran B, Piqueras M, Iglesias E, et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013;19(2):411–7.

    PubMed  Google Scholar 

  54. Masclee GM, Coloma PM, Kuipers EJ, Sturkenboom MC. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110(5):749–59.

    Article  CAS  PubMed  Google Scholar 

  55. Bonderup OK, Fenger-Gron M, Wigh T, Pedersen L, Nielsen GL. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis. 2014;20(10):1702–7.

    Article  PubMed  Google Scholar 

  56. Verhaegh BP, de Vries F, Masclee AA, Keshavarzian A, de Boer A, Souverein PC, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):1004–13.

    Article  CAS  PubMed  Google Scholar 

  57. Andersen T, Andersen JR, Tvede M, Franzmann MB. Collagenous colitis: are bacterial cytotoxins responsible? Am J Gastroenterol. 1993;88(3):375–7.

    CAS  PubMed  Google Scholar 

  58. Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut microbes. 2017;8(4):351–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Crowson MS, Shull GE. Isolation and characterization of a cDNA encoding the putative distal colon H+, K(+)-ATPase. Similarity of deduced amino acid sequence to gastric H+, K(+)-ATPase and Na+, K(+)-ATPase and mRNA expression in distal colon, kidney, and uterus. J Biol Chem. 1992;267(19):13740–8.

    CAS  PubMed  Google Scholar 

  60. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The microbiome and the respiratory tract. Annu Rev Physiol. 2016;78:481–504.

    Article  CAS  PubMed  Google Scholar 

  62. El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997;113(3):755–60.

    Article  CAS  PubMed  Google Scholar 

  63. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–8.

    Article  CAS  PubMed  Google Scholar 

  64. Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):120.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–42.

    Article  CAS  PubMed  Google Scholar 

  66. Qorraj-Bytyqi H, Hoxha R, Sadiku S, Bajraktari IH, Sopjani M, Thaci K, et al. Proton pump inhibitors intake and iron and vitamin B12 status: a prospective comparative study with a follow up of 12 months. Open Access Maced. J Med Sci. 2018;6(3):442–6.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821 e1–829 e1.

    Article  CAS  Google Scholar 

  68. Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672–4.

    Article  CAS  PubMed  Google Scholar 

  69. Golubov J, Flanagan P, Adams P. Inhibition of iron absorption by omeprazole in rat model. Dig Dis Sci. 1991;36(4):405–8.

    Article  CAS  PubMed  Google Scholar 

  70. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288–92.

    Article  CAS  PubMed  Google Scholar 

  71. Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger–Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12(1):83–98.

    Article  CAS  PubMed  Google Scholar 

  72. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53.

    Article  CAS  PubMed  Google Scholar 

  74. William JH, Danziger J. Proton-pump inhibitor-induced hypomagnesemia: current research and proposed mechanisms. World J Nephrol. 2016;5(2):152–7.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Zipursky J, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Paterson JM, et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case–control study. PLoS Med. 2014;11(9):e1001736.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Sharara AI, Chalhoub JM, Hammoud N, Harb AH, Sarkis FS, Hamadeh G. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin Gastroenterol Hepatol. 2016;14(2):317–21.

    Article  CAS  PubMed  Google Scholar 

  77. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–13.

    Article  CAS  PubMed  Google Scholar 

  78. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70–3.

    Article  CAS  PubMed  Google Scholar 

  79. Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O’Brien KO, Proctor DD, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Ziegler TE, Penniston KL, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2786–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74.

    Article  CAS  PubMed  Google Scholar 

  82. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.

    Article  CAS  PubMed  Google Scholar 

  83. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.

    Article  CAS  PubMed  Google Scholar 

  84. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.

    Article  CAS  PubMed  Google Scholar 

  86. Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  88. Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62(6):473–9.

    Article  CAS  PubMed  Google Scholar 

  89. Colmenares EW, Pappas AL. Proton pump inhibitors: risk for myopathy? Ann Pharmacother. 2017;51(1):66–71.

    Article  PubMed  Google Scholar 

  90. Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.

    Article  PubMed  Google Scholar 

  91. Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, et al. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS One. 2017;12(2):e0171006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153(4):971 e4–979 e4.

    Article  CAS  Google Scholar 

  93. Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol. 2017;112(12):1802–8.

    Article  CAS  PubMed  Google Scholar 

  94. Wod M, Hallas J, Andersen K, Garcia Rodriguez LA, Christensen K, Gaist D. Lack of association between proton pump inhibitor use and cognitive decline. Clin Gastroenterol Hepatol. 2018;16(5):681–9.

    Article  CAS  PubMed  Google Scholar 

  95. Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. Int Psychogeriatr. 2016;28(7):1059–65.

    Article  PubMed  Google Scholar 

  96. Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc. 2017;65(9):1969–74.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Badiola N, Alcalde V, Pujol A, Munter LM, Multhaup G, Lleo A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case–control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol. 2006;4(5):597–604.

    Article  CAS  PubMed  Google Scholar 

  100. Coca SG, Perazella MA. Early steroid treatment for drug-induced acute interstitial nephritis. Nat Clin Pract Nephrol. 2008;4(6):298–9.

    Article  PubMed  Google Scholar 

  101. Yang Y, George KC, Shang WF, Zeng R, Ge SW, Xu G. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Dev Ther. 2017;11:1291–9.

    Article  CAS  Google Scholar 

  102. Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P, Ungprasert P, Cheungpasitporn W. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. Dig Dis Sci. 2017;62(10):2821–7.

    Article  CAS  PubMed  Google Scholar 

  103. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. JASN. 2016;27(10):3153–63.

    Article  CAS  PubMed  Google Scholar 

  104. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482–94.

    Article  CAS  PubMed  Google Scholar 

  106. Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, et al. Results from the atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87(4):820–7.

    Article  CAS  PubMed  Google Scholar 

  107. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.

    Article  CAS  PubMed  Google Scholar 

  108. Eiselt J, Rajdl D, Racek J, Vostry M, Rulcova K, Wirth J. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study. Kidney Blood Pressure Res. 2014;39(1):50–7.

    Article  CAS  Google Scholar 

  109. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. JASN. 2014;25(4):657–70.

    Article  CAS  PubMed  Google Scholar 

  110. Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702–10.

    Article  CAS  PubMed  Google Scholar 

  111. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos Biol Fate Chem. 2010;38(1):92–9.

    Article  CAS  PubMed  Google Scholar 

  112. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–60.

    Article  CAS  PubMed  Google Scholar 

  113. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–44.

    Article  CAS  PubMed  Google Scholar 

  114. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713–8.

    Article  PubMed  PubMed Central  Google Scholar 

  115. prilosec IfhputtlocbmaPtahpaadiwomapa. United States Food and Drug Administration. https://wayback.archive-it.org/7993/20170406044850/. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm.

  116. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–97.

    Article  CAS  PubMed  Google Scholar 

  117. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474–82.

    Article  CAS  PubMed  Google Scholar 

  118. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.

    Article  CAS  PubMed  Google Scholar 

  119. Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016;129(9):1002–5.

    Article  CAS  PubMed  Google Scholar 

  120. Shell WE, DeWood MA, Peter T, Mickle D, Prause JA, Forrester JS, et al. Comparison of clinical signs and hemodynamic state in the early hours of transmural myocardial infarction. Am Heart J. 1982;104(3):521–8.

    Article  CAS  PubMed  Google Scholar 

  121. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475–84.

    Article  CAS  PubMed  Google Scholar 

  122. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157(1):148 e1–5.

    Article  CAS  PubMed  Google Scholar 

  123. Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract. 2015;21(3):194–200.

    Article  CAS  PubMed  Google Scholar 

  124. Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, et al. Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer. 2015;16(1):33–9.

    Article  CAS  PubMed  Google Scholar 

  125. Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257–63.

    Article  PubMed  Google Scholar 

  126. Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/logic randomized clinical trial. JAMA Oncol. 2017;3(6):767–73.

    Article  PubMed  Google Scholar 

  127. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310(18):1137–40.

    Article  CAS  PubMed  Google Scholar 

  128. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016;64(6):1893–9.

    Article  CAS  PubMed  Google Scholar 

  129. Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca–Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995;39(8):1671–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–66.

    Article  CAS  PubMed  Google Scholar 

  131. Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26(3):341–6.

    Article  CAS  PubMed  Google Scholar 

  132. Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JB, Lamers CB, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol. 1992;42(3):319–24.

    Article  CAS  PubMed  Google Scholar 

  134. Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, Wurst W. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther. 1996;34(1 Suppl):S81–5.

    CAS  PubMed  Google Scholar 

  135. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Cohen AF, Kroon R, Schoemaker R, Hoogkamer H, van Vliet A. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med. 1991;115(7):540–5.

    Article  CAS  PubMed  Google Scholar 

  137. Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther. 1996;34(1 Suppl):S67–71.

    CAS  PubMed  Google Scholar 

  138. Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29(1):35–50.

    Article  CAS  PubMed  Google Scholar 

  139. Hughes GS, Heald DL, Barker KB, Patel RK, Spillers CR, Watts KC, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989;46(6):674–85.

    Article  CAS  PubMed  Google Scholar 

  140. Grasela TH Jr, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ, Schultz RW, et al. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989;33(5):615–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol. 2005;45(7):845–50.

    Article  CAS  PubMed  Google Scholar 

  142. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58(3):288–98.

    Article  CAS  PubMed  Google Scholar 

  143. Bell JS, Strandberg TE, Teramura-Gronblad M, Laurila JV, Tilvis RS, Pitkala KH. Use of proton pump inhibitors and mortality among institutionalized older people. Arch Intern Med. 2010;170(17):1604–5.

    PubMed  Google Scholar 

  144. Wilson N, Gnjidic D, March L, Sambrook P, Hilmer SN. Use of PPIs are not associated with mortality in institutionalized older people. Arch Intern Med. 2011;171(9):866 (author reply-7).

    Article  PubMed  Google Scholar 

  145. Teramura-Gronblad M, Bell JS, Poysti MM, Strandberg TE, Laurila JV, Tilvis RS, et al. Risk of death associated with use of PPIs in three cohorts of institutionalized older people in Finland. J Am Med Direct Assoc. 2012;13(5):488 e9–513 e9.

    Article  Google Scholar 

  146. Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Butto V, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518–23.

    Article  PubMed  PubMed Central  Google Scholar 

  147. de Francisco ALM, Varas J, Ramos R, Merello JI, Canaud B, Stuard S, et al. Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. Kidney Int Rep. 2018;3(2):374–84.

    Article  PubMed  Google Scholar 

  148. Pegoli MA, Dedigama M, Mangoni AA, Russell PT, Grzeskowiak LE, Thynne T. Proton pump inhibitors and risk of readmission and mortality in older patients discharged from a tertiary hospital to residential aged care facilities. Ther Adv Drug Saf. 2017;8(4):137–9.

    Article  PubMed  Google Scholar 

  149. Pello Lazaro AM, Cristobal C, Franco-Pelaez JA, Tarin N, Acena A, Carda R, et al. Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease. PLoS One. 2017;12(1):e0169826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228–34.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Gastroenterology, Department of Internal Medicine, Rady School of Medicine, University of Manitoba, 805G-715 McDermot Avenue, Winnipeg, MB, R3E 3P4, Canada

    Evan Elias & Laura E. Targownik

Authors
  1. Evan Elias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura E. Targownik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura E. Targownik.

Ethics declarations

Funding

No funding was received for the preparation of this manuscript

Conflicts of Interest

Evan Elias has no conflicts of interest to declare. Laura E. Targownik has no conflicts of interest to declare that directly relate to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elias, E., Targownik, L.E. The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events. Drugs 79, 715–731 (2019). https://doi.org/10.1007/s40265-019-01110-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01110-3

Search

Navigation